Moffitt Cancer Center Logo
 

Treatment and Clinical Trials

Where You Are:

 

What treatments are available at Moffitt Cancer Center?
A vast array of treatment options is routinely offered at Moffitt Cancer Center. Moffitt Cancer Center uses a multidisciplinary approach in which multiple physicians with various relevant expertise teamed up to make treatment plan for one patient. In addition, each patient’s unique medical, social, and financial is taken into consideration. A limited list of service offered includes:

  • Surgery: Extrapleural Pneumonectomy (EPP), Pleurectomy, Decortication , Robotic-Assisted Surgery
  • Radiation: Intensity Modulated Radiation Therapy (IMRT), Tomotherapy, Brachy therapy
  • Chemotherapy: Heated Intraoperative Peritoneal Chemotherapy (HIPEC)
  • Clinical trials: Clinical trials represent the cutting edge, best available option for any cancer treatment. See if one is right for you.

Radiation Therapy

Mesothelioma requires fairly large doses of radiation. Unfortunately, mesotheliomas occur in regions of the body that are often sensitive to radiation. Intensity Modulated Radiation Therapy (or IMRT) is required to safely deliver effective doses of radiation to mesotheliomas. This technique reduces, but does not eliminate, normal tissue effects.

We are pioneers in the development of IMRT for mesothelioma. Dr. Stevens published the first papers on the use of IMRT for mesothelioma in 2002, and has been actively developing and improving techniques since then. Moffitt uses TomoTherapy technology to comprehensively treat patients with mesothelioma that require entire pleural radiation. This has been done successfully in patients that have undergone surgery and those that have not. Post-operative treatment offers the best chance for cure, however.

Clinical Trials

Moffitt Cancer Center’s Mesothelioma Research and Treatment Center offers cutting- edge treatment options for patients diagnosed with Mesothelioma. There is a strong emphasis on clinical research to develop novel treatment options utilizing immunotherapy and therapeutic vaccines. At this time, clinical trials specific for pleural mesothelioma include:

A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS 207 in Combination with Pemetrexed and Cisplatin as Front-Line Therapy in Adults with Malignant Pleural Mesothelioma (MCC 17101). Learn more about this clinical trial.

Principal Investigator: Scott Antonia, MD, PhD
Clinical Trial Coordinator: Melissa Joiner, RN

Key Eligibility Criteria:

  • Confirmed mesothelioma
  • Never been treated with chemotherapy

Why this treatment is promising
Standard treatment of mesothelioma is combined pemetrexed and cisplatin. This clinical trial further enhances the success of this combo by adding CRS-207. CRS-207 is a vaccine which helps boost our immune system to target mesothelin. Mesothelin is expressed overly in malignant mesothelioma cells. Therefore, this clinical trial not only directly kills the cancer cells by using chemotherapy, but also indirectly promotes the patient’s cells to help fight off cancer.

A Phase 2 Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma (MCC 17367 Opening Soon)

Principal Investigator: Scott Antonia, MD, PhD 
Clinical Trial Coordinator: Amanda Carpenter

Contact Information:

Scott.Antonia@moffitt.org

Key Eligibility Criteria:

  • Confirmed mesothelioma
  • 2nd /3rd Line: Previously treated with chemotherapy
 
 
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer